• Save
Phamaceutical sector in india
Upcoming SlideShare
Loading in...5
×
 

Phamaceutical sector in india

on

  • 1,050 views

This ppt gives an overview of the Indian Pharmaceutical sector. We have concentrated on 5 aspects of the sector and analysed it. The covered heads are history, business model, Marketing, Competitor ...

This ppt gives an overview of the Indian Pharmaceutical sector. We have concentrated on 5 aspects of the sector and analysed it. The covered heads are history, business model, Marketing, Competitor analysis, Financials and Trends.

Statistics

Views

Total Views
1,050
Views on SlideShare
1,050
Embed Views
0

Actions

Likes
1
Downloads
0
Comments
1

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
  • Dear uploader..!!
    Can you please mail me the ppt (ashlesharaikar92@gmail.com)
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • Report by IAMAI(internet and mobile association of india & IMRB, growth of 16% compared to last year. MOBILE – 6 million -11.2 million

Phamaceutical sector in india Phamaceutical sector in india Presentation Transcript

  • Indian Pharmaceutical Sector A presentation by Deepak Kumar Dipankar Biswas Kasif Iqbal Partho Sarathi Roy Shireen Khan
  • Inception & Snapshot Bengal $21.73 Chemicals and 1.4 million Pharmaceuticals billion employment (1892) industry per year Alembic Chemical works (1907) Bengal Immunity (1919) Ranks 10 % of among topCalcutta Chemicals, Standard global five Pharmaceuticals, production countries Indian Cipla etc. by volume PharmacGSK, Parke Davis, eutical Wyeth, Ciba etc. Sector
  • Time for Big Boys 1 2 3HindustanAntibiotics IDPL (1961) Ranbaxy (1954) (1961) Evolution of Major Drugs1920 1930 1940 1948
  • Game Changing Move LandmarkIDMA was formed Patent act wasin 1961 passed in 1970 India couldAim was to oppose manufacture anymonopoly international drug
  • Division of Drugs Chronic Therapy Acute Therapy Segment Segment Indian Pharmaceutical IndustryBulk drugs or Formulations API Cardiovascular Anti infective Neurological Gastro intestinal Anti-diabetes Respiratory Oncology Pain management
  • Location of major pharmaceutical companies in India 4000 3500 3000 No. of Companies 2500 2000 1500 1000 500 0 Others Tamil Nadu Maharashtra Gujrat West Bengal Andhra Pradesh Formulations Bulk Drugs
  • Top Players Ranbaxy Sun PharmaceuticalsDr. Reddy’s Labortories Ltd. Cipla Lupin
  • Strength Vast market growth potential Low cost production Low R&D costs Innovative manpower Cheap/skilled English-speaking labor force Increasing western work methods and mindset Long-established trade patterns with Western Europe and the US Strong local manufacturing sector Governmental focus and investment in the R&D area Increasing FDI in the industry
  • Weakness Low pharma consumption levels per capita Biased drug pricing and bad compensation policy Underdeveloped healthcare infrastructure Vast regional disparities in healthcare coverage Many pharma MNCs already supplying the market at lower prices
  • Opportunities Large and growing population Rising demand for generic drugs globally Increased demand for APIs – active pharmaceutical ingredients Increasing R&D activity by domestic firms
  • Threats Failure to properly enforce WTO compliant patent legislation for drugs. Government imposing further price controls on essential medicine India’s patent laws threatened by litigation Weak copy right policies threatening the legal entities in the industry
  • Porter’s Five Force Model Power of supplier  Very low bargaining power Threat of Substitutes Barriers to Entry Industry Competition  No substitute for the Very low barrier to medicine entry  Highly competitive  Biotechnology is a threat to synthetic pharma product Power of Buyers  Consumer has no choice but to buy what doctor says
  • Industry Competition Most competitive industries in the country with as many as 10,000 different players. Top player in the country has only 6% market share and top five have 18%. High growth prospects. Very low entry barriers. Fixed cost requirement is low and need for working capital is high.
  • Bargaining Power of Buyers End user of the product is different from the influencer (read Doctor). Consumer has no choice but to buy what doctor says. Buyers are scattered and they as such does not wield much power in the pricing of the products.
  • Bargaining Power of Suppliers Pharma industry depends upon several organic chemicals. Very competitive and fragmented industry. Chemicals are largely a commodity. Suppliers have very low bargaining power. Pharma industry can switch from their suppliers without incurring a very high cost.
  • Barriers to Entry Most easily accessible industries for an entrepreneur in India. Capital requirement for the industry is very low, creating a regional distribution network is easy. Point of sales is restricted in this industry in India. Creating brand awareness and franchisee amongst doctors is the key for long-term survival. Quality regulations by the government may put some hindrance for establishing new manufacturing operations. Impending new patent regime will raise the barriers to entry.
  • Threat of Substitutes One of the great advantages of the pharma industry. Demand for pharma products continues and the industry thrives. Key reasons for high competitiveness in the industry is that as an on going concern. Key reasons for high competitiveness in the industry is that as an on going concern.
  • Revolution in Marketing International Trade Barriers have disappeared Indian Industry is competing globally Evolution of Internet, giving access to whole lot of information, 137 million internet connection in india Evolution of smart phones (sales growth by 87%) Recognition of India’s intellectual capabilitiesReport by: IAMAI, IMRB & Cyber Media Research
  • Global Pharma Market Market Growth Market size Market Growth Forecast Region Yr 2008 ( USD CAGR (2003 - Billion) 2008) CAGR (2011 - 2015) North America 311.8 5.70% -1% to 2% Europe 247.5 6.40% 3% to 6% Japan 76.6 2.70% 1% to 4% China 21 20% 23% India 7.7 14.60% 12.20%Global Sales 773.2 6.60% 3% to 6%
  • Promotions Gifting Detailing Drug Samples Sponsoring Continuing Medical Education (CME)
  • Pull & Push Marketing SystemSuper Core Model (Pull System) Core Model (Push System)
  • Operation & Distribution of Pharmaceutical Industry
  • Supply Chain ModelManufacturer Repackager Retailer Wholesaler Manufacturer Retailer Repackager Wholesaler Wholesaler Manufacturer Retailer Other Sources of Drugs (foreign, private mfrs)
  • Challenges in Pharma Supply Chain Supply Inventory chain cost effectiveness Logistic Planning effectiveness SupplyTime to chain Responsivenessmarket challenges
  • Margins at Different LevelLevels MarginsClearing and forwarding agents 1–10% on the total turnover + other expensesStockist or distributors 8% on scheduled drugs 10% on nonscheduled drugsRetailers 16% on scheduled drugs 20% on nonscheduled drugs
  • Balance Sheet OverviewCompanies Market Cap Sales Turnover Net Profit AssetsName Rs. in CroresRanbaxy Labs 21,551.69 7,690.12 -3,052.05 6,258.36Sun Pharma 78,776.72 4,015.56 1,927.98 8,148.91Cipla 34,758.47 6,977.50 1,123.96 7,562.48Dr Reddys 32,607.28 6,739.70 912.36 8,251.20LabsLupin 26,750.90 5,384.83 804.37 4,727.06
  • DuPont Analysis Cipla pharmaceutical ROE and ROI has highest returns on equity and Investment by 23.10 and 0.21 followed by Dr. Reddy’s Laboratories ROE is 17.00 and ROI is 0.18. The third position secured by Ranbaxy Laboratories ROE is 16.16 and ROI by 0.13. This shows Cipla is concentrating on its financial performance by reducing its expenses and cost. Company Logo
  • Total Pharmaceutical Market Share(India) 1.7 10.9 Anti-Infective 4.4 11 16.4 Gastrointestinal5.3 Cardiac Respiratory5.3 Vit./Minerals/Nutrients Pain/Analgesics Dermatologists Gynaecology5.4 9.6 Neuro psychiatry antidiabetics 9.5 10.3 Opthologicals 10.2 Others Company Logo
  • Cost Structure Ranbaxy Sun Pharma 1400 3000 1200 2500 1000 2000 Rs. in Crores 800Rs. in Crores 1500 600 1000 400 200 500 0 Raw Power Emplo Other Selling Miscel 0 Materi & Fuel yee Manuf & laneou Raw Power Emplo Other Selling Miscell als cost cost acturin Admin s exp Materi & Fuel yee Manuf & aneou g cost exp als cost cost acturin Admin s exp 2010 878.46 47.38 174.71 52.9 439.11 31.92 g cost exp 2011 928.85 39.4 214.06 62.81 505.7 27.69 2010 2181.2 132.75 608.28 96.68 1332.7 185.14 2012 1257.7 68.76 316.56 34.86 0 660.7 2011 2523.0 194.98 845.24 112.69 1579.3 1283.5
  • Cost Structure Dr. Reddys Cipla 3500 2500 3000 2000 2500 Rs. in Crores 1500Rs. in Crores 2000 1500 1000 1000 500 500 0 0 Raw Power Emplo Other Selling Miscell Raw Power Employ Other Selling Miscell Materi & Fuel yee Manuf & aneous Materia & Fuel ee cost Manufa & aneous als cost cost acturin Admin exp ls cost cturing Admin exp g cost exp cost exp 2010 1599.4 104.1 516.4 117.3 1036.6 50.6 2010 2687.54 92.15 318.87 259.67 867.98 182.64 2011 1749.5 144.6 702.7 129.5 1256.7 65 2011 3085.9 164.42 464.2 270.08 999.68 179.49 2012 2122.9 177.5 831.2 163.1 1554.4 80.3 2012 2903.95 188.18 644.79 259.56 1217.79 154.27
  • Cost Structure Lupin 2500 2000Rs. in Crores 1500 1000 500 0 Raw Materials Power & Fuel Employee cost Other Selling & Admin Miscellaneous cost Manufacturing exp exp cost 2010 1596.77 141.68 376.55 115.15 562.13 54.72 2011 1921.18 196.83 491.23 99.35 653.62 134.69 2012 2377.44 257.13 579.67 119.15 804.2 153.75
  • Cost Structure YOY Cost structure S.NO 2010-11 2011-12 7000 Sun 6000 9.48% 31.5% Pharma 5000Figure in crores 4000 Ranbaxy 44.13% 3000 Lupin 22.8% 22.7% 2000 1000 Cipla 17.1% 4% 0 Sun Pharma Ranbaxy Lupin Cipla Dr. Reddys Dr. 2010 1624.48 4536.77 2847 4408.85 3424.4 18.2% 21.8% 2011 1778.51 6538.9 3496.9 5163.77 4048 Reddy’s 2012 2338.67 4291.34 5368.54 4929.4
  • Acquisitions by MNCsNo Year Acquirer Target Company Company Country1 Jun’08 Daiichi Sankyo Co Ltd Japan Ranbaxy Laboratories2 Aug’08 Fresenius Kabi AG Germany Dabur Pharma3 Jun’09 Pfizer (Animal Health U.S. Vetnex Animal Health Ltd Business) (earlier ICICI Venture acquired from Ranbaxy)4 Jun’09 Vetoquinol SA France Wockhardt (Animal Care Subsidiary)5 Jul’09 Abbott Laboratories U.S. Wockhardt (Nutrition Business)6 Jul’09 Sanofi Aventis France through Shantha Biotech (Hiked stake Merieux Alliance from 60% to 80%)7 May’10 Abbott Laboratories USA Piramal Healthcare(Sale of Business)
  • Trends in DiseasesTuberculosisEspecially in urban centres like Mumbai, Delhi, Hyderabad, Kolkata etc.Dengue Fever- 97 % increase in number of cases and 34 % increase in number of deathsSwine flu- Worst affected areas are MP, UP, RajasthanEncephalitis- 50% decrease in the last 2 years, lack of funds could play spoilsportsLifestyle diseases- Heart diseases, Cancer, Obesity, Diabetes etc. is set to rise
  • Clinical Trial Boom  Huge amount of outsourcing from Europe and USA  Highly trained man power  Advanced IT infrastructure  Large amount of patients to experiment  Expected to employ 50,000 medical professionals by 2017WHO report, 2011
  • Recommendations Stringent patent laws must be imposed. Many patents are rejected by USPTO and EPO. Pharmaceuticals mergers and acquisition should be scanned closely by the Competition commission of India Price regulation should be balanced in such a way that it does not affect the Pharmaceutical business Assisting SME’s in overcoming entry barriers posed by GMP compliance requirement Absence of provision on regulation of biosimilars Transparency and accountability in the drug regulatory regime